Page 13 - Read Online

Örmeci. Hepatoma Res 2019;5:11 I http://dx.doi.org/10.20517/2394-5079.2019.14 Page 7 of 7

antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol
and Ther 2018;47:516-25.
22. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated
cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411-21.
23. Marco VD, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, et al. Effects of eradicating hepatitis C virus infection in patients with
cirrhosis differ with stage of portal hypertension. Gastroenterology 2016;151:130-9.
24. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gastroenterology 2017;153:996-1005.
25. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, et al. Newly diagnosed hepatocellular carcinoma in patients with
advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol 2018;69:345-52.
26. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, et al. Systematic review and meta-analysis of interferon after
curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975-81.
27. Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, et al. The impact of direct-acting antivirals on early tumor recurrence after
radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016;65:1261-73.
28. Idilman R, Demir M, Aladag M, Erol C, Cavus B, et al. Low recurrence rate of Hepatocellular carcinoma following Ledipasvir and
Sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. J Viral Hepat 2019; doi: 10.1111/jvh.13075.